Patents by Inventor Viviana BOZON

Viviana BOZON has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • DOSAGE REGIMENS FOR PARP7 INHIBITORS
    Publication number: 20220265654
    Abstract: The present invention is directed to dosing, dosage regimens, formulations, unit dosage forms, and related, of a PARP7 inhibitor for the treatment of cancer. The present invention is also directed to methods of treating cancer by administering the PARP7 inhibitor in combination with an antibody that binds to PD-1.
    Type: Application
    Filed: February 15, 2022
    Publication date: August 25, 2022
    Inventors: Melissa Marie Vasbinder, Lucas J. Utley, Viviana Bozon, Kevin Wayne Kuntz, Sudha Parasuraman, William McCulloch, Nolan Wood
  • COMBINATION OF RAF INHIBITORS AND TAXANES
    Publication number: 20200316067
    Abstract: The present disclosure relates to methods for the treatment of cancers. In particular, the disclosure provides methods for treatment of cancer by administering a Raf inhibitor in combination with a taxane. The present disclosure relates to methods of treating a subject suffering from cancer, comprising administering to the subject: (i) a Raf kinase inhibitor or a pharmaceutically acceptable salt thereof; and (ii) a taxane or a pharmaceutically acceptable salt thereof; the amount of the Raf kinase inhibitor and taxane or a pharmaceutically acceptable salt thereof is such that the combination thereof is therapeutically effective in the treatment of the cancer.
    Type: Application
    Filed: June 1, 2020
    Publication date: October 8, 2020
    Inventors: Viviana Bozon, Katherine M. Galvin, Rachael L. Brake, Qunli Xu, Karuppiah Kannan
  • Pharmaceutical formulations of a pan-RAF kinase inhibitor and processes for their preparation
    Patent number: 10426782
    Abstract: The invention relates to a pharmaceutical composition comprising Compound 1 or a pharmaceutically acceptable salt thereof for the treatment of cancer and a process for its preparation. The invention also relates to administering the pharmaceutical composition to a patient according to an intermittent dosing regimen.
    Type: Grant
    Filed: March 26, 2015
    Date of Patent: October 1, 2019
    Assignee: MILLENNIUM PHARMACEUTICALS, INC.
    Inventors: Rachael L. Brake, Viviana Bozon, Ching-Kuo J. Chow, James C. Dinunzio, Katherine M. Galvin, Karuppiah Kannan, Yuki Kodono, Qunli Xu
  • COMBINATION OF RAF INHIBITORS AND TAXANES
    Publication number: 20190117652
    Abstract: The present disclosure relates to methods for the treatment of cancers. In particular, the disclosure provides methods for treatment of cancer by administering a Raf inhibitor in combination with a taxane. The present disclosure relates to methods of treating a subject suffering from cancer, comprising administering to the subject: (i) a Raf kinase inhibitor or a pharmaceutically acceptable salt thereof; and (ii) a taxane or a pharmaceutically acceptable salt thereof; the amount of the Raf kinase inhibitor and taxane or a pharmaceutically acceptable salt thereof is such that the combination thereof is therapeutically effective in the treatment of the cancer.
    Type: Application
    Filed: December 22, 2015
    Publication date: April 25, 2019
    Applicant: MILLENNIUM PHARMACEUTICALS, INC.
    Inventors: Viviana BOZON, Katherine M. GALVIN, Rachael L. BRAKE, Qunli XU, Karuppiah KANNAN
  • COMBINATION OF RAF INHIBITORS AND AURORA KINASE INHIBITORS
    Publication number: 20180263979
    Abstract: The present disclosure relates to methods for the treatment of cancers. In particular, the disclosure provides methods for treatment of cancer by administering Raf inhibitors in combination with Aurora kinase inhibitors. The present disclosure relates to methods of treating subject suffering from cancer, comprising administering to the subject a Raf kinase inhibitor or a pharmaceutically acceptable salt thereof; and an Aurora kinase inhibitor or a pharmaceutically acceptable salt thereof; the amount of said Raf kinase inhibitor or a pharmaceutically acceptable salt thereof being such that the combination thereof is therapeutically effective in the treatment of the cancer. In some [embodiments, the cancer is a solid tumor cancer.
    Type: Application
    Filed: December 22, 2015
    Publication date: September 20, 2018
    Applicant: MILLENNIUM PHARMACEUTICALS, INC.
    Inventors: Viviana BOZON, Katherine M. GALVIN
  • PHARMACEUTICAL FORMULATIONS OF A PAN-RAF KINASE INHIBITOR, PROCESSES FOR THEIR PREPARATION, AND METHODS OF USE
    Publication number: 20170173033
    Abstract: The invention relates to a pharmaceutical composition comprising Compound 1 or a pharmaceutically acceptable salt thereof for the treatment of cancer and a process for its preparation. The invention also relates to administering the pharmaceutical composition to a patient according to an intermittent dosing regimen.
    Type: Application
    Filed: March 26, 2015
    Publication date: June 22, 2017
    Inventors: Rachael L. BRAKE, Viviana BOZON, Ching-Kuo J. CHOW, James C. DINUNZIO, Katherine M. GALVIN, Karuppiah KANNAN, Yuki KODONO, Qunli XU